Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Public Health Res ; 10(1): 1860, 2021 Jan 14.
Article in English | MEDLINE | ID: mdl-33489991

ABSTRACT

Background: Though there was a high blood supply need in response to high communicable disease and increased emergency conditions; the practice of health professionals and non-health professionals on voluntary blood donation is still unexpectedly low in Ethiopia. Health professionals and non-health professionals working in the health sectors are pivotal in taking the lead to reverse the effect of inadequate blood supply system in the country. Therefore, the study aimed to understand the level and contributing factors of knowledge, attitude and practice of voluntary blood donation among health and non-health professionals in ALERT Hospital, Addis Ababa, Ethiopia. Design and Methods: A cross-sectional study design was conducted among health professionals and non-health professionals in ALERT hospital from 5 to 30 June 2018. A total of 394 hospital staffs participated in this study. A well-structured self-administered questionnaire was used to assess the knowledge, attitude, and practice about voluntary blood donation. The statistical analysis was carried out using R. Results: A total of 203 (51.5%) participants were females. Only 142(36%) of the participants had voluntary blood donation practice. Among these, 60 (42.3%) of them were donated blood more than once. Occupation is the only factor significantly associated with blood donation practice; health professionals had almost two-fold donation practice than non-health professionals (AOR=1.62; 5% CI: 1.02, 2.57, p=0.042). Occupation has also a strong relationship with knowledge, health professionals had better knowledge than non-professionals with (AOR=2.39; 95% CI: 1.39, 4.12; p=0.002). The result also showed that the educational status of the participants was strongly associated with the blood donors' attitude with (AOR=3.62; 95%CI: 1.1, 11.93, p=0.035). One hundred and two (72.3%) of the blood donors were motivated to donate blood for charity, 133 (94.3%) individuals were felt good after blood donation and lack of request was the major reason 88.6% that causes the respondents not to donate blood frequently. Conclusions: Low blood donation practice of health professionals and non-health professionals was identified from this study. Occupation had significantly associated with blood donation practice. Therefore, targeted interventions aimed at mobilizing hospital staffs and develop accessible blood donation centers are recommended to reverse the effect of inadequate blood supply system in Ethiopia.

2.
BMC Med Res Methodol ; 19(1): 192, 2019 10 15.
Article in English | MEDLINE | ID: mdl-31615422

ABSTRACT

BACKGROUND: Locally produced generic drugs offer a cost-effective alternative to imported drugs to treat patients in Ethiopia. However, due to a lack of bioequivalence testing, additional assurance tests are needed to build trust in cheaper, locally made drugs. By testing bioequivalence of local drugs to gold standard, N-of-1 tests have the potential to promote patient centred quality use of medicines. METHOD: We sought to assess the acceptability of, and explore barriers to, conducting N-of-1 tests to evaluate local medicines in a resource limited clinical setting. We conducted a descriptive qualitative study, analysing four focus group discussions and five key informant interviews. Participants were senior drug regulatory authority members, institutional review board members, physicians and patients. All interviews were audio taped and transcribed verbatim. Patient interviews were conducted in Amharic and translated to English prior to analysis. Data analysis used an inductive, thematic process. RESULTS: Five major themes were identified; (1) Appropriateness of N-of-1 tests to determine the therapeutic equivalence of local drugs, (2) N-of-1 therapeutic equivalence tests: clinical care or research? (3) Ethical and regulatory requirements (IRB), (4) Potential barriers to implementing N-of-1 tests and (5) Possible solutions to identified challenges. The study demonstrated considerable support for using N-of-1 tests for clinical equivalence studies between local and imported medicines, but important impediments were very likely to impact the feasibility of conducting N-of-1 tests in Ethiopia. Key informants from the regulatory authority did not support additional tests of local drugs. There were also mixed opinions regarding ethical requirements for conducting N-of-1 tests. The Institutional Review Board (IRB) members believed that IRB approval was sufficient to conduct N-of-1 tests, however, the regulatory authority members considered that N-of-1 tests constituted a clinical trial, and required approval at the regulatory level. CONCLUSION: This study showed that there were key uncertainties that could impact the feasiblity of using N-of-1 testing local drugs in Ethiopia. Therefore, a number of protocol amendments to address contextual threats and regulatory challenges, would be needed before progressing to conducting these tests.


Subject(s)
Drug and Narcotic Control , Drugs, Generic/pharmacology , Therapeutic Equivalency , Drug Substitution , Ethics Committees, Research , Ethiopia , Focus Groups , Humans , Physicians/psychology , Qualitative Research
3.
Eur J Cancer Care (Engl) ; 28(3): e13057, 2019 May.
Article in English | MEDLINE | ID: mdl-31020737

ABSTRACT

Core components of survivorship care include treatment of late and long-term effects, care coordination, promotion of psychological well-being, health and addressing special populations' needs. Women affected by gynaecological cancer and their caregivers can experience disease-specific issues. This review presents an overview of survivorship interventions that have been trialled among this population. Databases were searched in October/November 2016 to identify eligible studies. Titles, abstracts then full-text were assessed for inclusion by two reviewers until consensus was reached. Data were abstracted using standard tables. Study quality was independently appraised. Twenty-eight articles were included (five reviews; 23 trials). In regards to late and long-term treatment effects, our review found mounting high-level evidence for the effectiveness of psycho-educational programmes to improve physical aspects of sexual function and for exercise interventions for reducing fatigue. We also found emerging evidence for nurse-led follow-up care to improve care coordination and cognitive behavioural therapy to improve psychological wellbeing. There were gaps in the evidence for interventions to effectively address psychosexual issues specific to gynaecological cancer and needs of caregivers. Further research is required to explore strategies to improving psychosexual concerns after gynaecological cancer and the dynamics and supportive care needs of the patient-partner dyad.


Subject(s)
Cancer Survivors , Caregivers , Genital Neoplasms, Female/rehabilitation , Aftercare , Cognitive Behavioral Therapy , Exercise , Fatigue , Fecal Incontinence , Female , Humans , Lymphedema , Patient Education as Topic , Practice Patterns, Nurses' , Sexual Health , Urinary Incontinence
4.
BMC Health Serv Res ; 18(1): 624, 2018 08 08.
Article in English | MEDLINE | ID: mdl-30089496

ABSTRACT

BACKGROUND: Because of their cost, the use of locally produced, bioequivalent, generic drugs is universally recommended. In Ethiopia. while the government is committed to raising the market share and use of locally produced drugs, the process is hampered by the lack of a bioequivalence testing centre to strengthen the regulatory environment and deliver quality-assured local medicines. The purpose of this study is to assess the views and perceptions of key regulatory stakeholders, physicians and patients about locally produced generic medicines. METHODS: A descriptive qualitative study, using focus group discussions and key informant interviews, was conducted. Five key informant interviews (two senior regulatory authority members and 3 institutional review board members) as well as 4 focus group discussions (2 with physicians and 2 with patients) were held. Data were analysed using an inductive, thematic process. RESULTS: Four major themes emerged: awareness of lack of bioequivalence profiles associated with local medicines, perceptions about the quality and effectiveness of local medicines, quality and efficacy of imported medicines from developing countries and quality and efficacy of cheaper medicines. All institutional review board members were aware of bioequivalence issues. However, many physicians lacked detailed knowledge about bioequivalence, its clinical relevance and the lack of bioequivalence data for local medicines. All institutional review board members, physicians and male patients, but not female patients, were concerned about the quality and effectiveness of local medicines. Female patients were more confident about the locally produced drugs. In addition, some physicians and patients were not confident about the quality and effectiveness of cheaper drugs and drugs imported from developing countries. Government officials believed that local drugs are reliable. CONCLUSION: The success of promoting the use of inexpensive local medicines and changing the perception of the community depends not only on increasing the domestic market share held by local companies, but also on the capacity of the regulatory environment and companies to produce quality assured medicines and to overcome misconceptions. Among other initiatives, establishing an accredited bioequivalence centre in the country needs to be addressed urgently.


Subject(s)
Drugs, Generic/standards , Health Knowledge, Attitudes, Practice , Adolescent , Adult , Aged , Attitude of Health Personnel , Commerce , Developing Countries , Drugs, Generic/pharmacokinetics , Ethiopia , Female , Focus Groups , Humans , Male , Middle Aged , Perception , Physicians/psychology , Qualitative Research , Therapeutic Equivalency , Young Adult
5.
Trials ; 19(1): 246, 2018 Apr 23.
Article in English | MEDLINE | ID: mdl-29685163

ABSTRACT

BACKGROUND: N-of-1 trials have a potential role in promoting patient-centered medicine in developing countries. However, there is limited academic literature regarding the use of N-of-1 trials in the clinical care of patients in resource-poor settings. OBJECTIVE: To assess the extent of use, purpose and treatment outcome of N-of-1 trials in developing countries. METHOD: A systematic review of clinical N-of-1 trials was conducted between 1985 and September 2015 using PubMed, Embase, CINAHL, Web of Science and the Cochrane Central Register of Controlled Trials. Grey literature databases and clinical trial registers were also searched. This review included randomized, multi-cycle, crossover within individual patient trials involving drug intervention. Quality assessment and data extraction were conducted by two independent reviewers. RESULT: Out of 131 N-of-1 trials identified, only 6 (4.5%) were conducted in developing countries. The major reason that N-of-1 trials were used was to provide evidence on feasibility, effectiveness and safety of therapies. A total of 72 participants were involved in these trials. Five of the studies were conducted in China and all evaluated Chinese traditional medicine. The remaining study was conducted in Brazil. The completion rate was 93%. More than half, 46 (69%) of subjects made medication changes consistent with trial results after trial completion. A number of threats to the validity of the included evidence limited the validity of the evidence. In particular, the estimated overall effect in four of the included studies could have been affected by the "carry over" of the previous treatment effect as no adequate pharmacokinetic evidence regarding traditional medicines was presented. CONCLUSION: The prevalence and scope of N-of-1 trials in developing countries is low. A coordinated effort among government, clinicians, researchers and sponsor organizations is needed to increase their uptake and quality in developing countries. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015026841 .


Subject(s)
Developing Countries , Patient Selection , Patient-Centered Care/methods , Randomized Controlled Trials as Topic/methods , Sample Size , Brazil , China , Endpoint Determination , Humans , Treatment Outcome
6.
Int J Equity Health ; 17(1): 37, 2018 Mar 22.
Article in English | MEDLINE | ID: mdl-29566721

ABSTRACT

BACKGROUND: Clinical trials for identification of efficient and effective new diagnostic and treatment modalities are needed to address disproportionately high burden of communicable (e.g., HIV/AIDS, tuberculosis, and malaria) and non-communicable diseases (e.g., diabetes) in developing countries. However, gross under-representation in global clinical trial platforms contributes to sustained health inequity in these countries. We reviewed the literature on barriers facing clinical researchers in developing countries for conducting clinical trials in their countries. METHODS: Literature indexed in PubMed, Embase, CINAHL and Web of Science, WHO Global Health Library were searched. Grey literature was also searched. Search key words included barriers, challenges, clinical trials and developing countries. Articles within the scope of this review were appraised by two reviewers. RESULTS: Ten studies, which are reported in 15 papers, were included in this review. Following critical review we identified five unifying themes for barriers. Barriers for conducting clinical trials included lack of financial and human capacity, ethical and regulatory system obstacles, lack of research environment, operational barriers and competing demands. CONCLUSION AND RECOMMENDATION: There were substantial barriers at system, organization and individual level. We propose that to address this problem, instituting a system for wider implementation of local investigator-initiated trials is warranted. These trials are more applicable to local populations because they build on local healthcare knowledge. They are more demand-led, influence policy and responsive to a country's needs because they are driven by a local or national agenda.


Subject(s)
Attitude to Health , Clinical Trials as Topic/organization & administration , Communication Barriers , Developing Countries , Humans , Research Support as Topic/organization & administration
7.
Support Care Cancer ; 26(3): 701-710, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29204708

ABSTRACT

PURPOSE: This review aimed to determine the prevalence of met and unmet needs, and the risk factors for unmet needs among people affected by gynaecological cancer. METHODS: The review was undertaken using the PRISMA guidelines. Eligible studies were identified though a range of electronic databases in October and November 2016. Study quality was independently appraised by two people. RESULTS: Thirty-seven studies were included (1 review, 24 quantitative and 12 qualitative). The evidence was of mixed quality. The total burden of needs affecting women with gynaecological cancer and also their caregivers predominately related to comprehensive care and psychological concerns. The major moderate-to-high-level unmet needs of women with gynaecological cancer were for help explicitly with fear of recurrence, worries of caregivers and fatigue, and for women who developed lymphoedema were with pain and associated costs. Qualitative studies identified disease-specific needs related to sexuality issues (including fertility, sexual functioning, relationship concerns, managing vaginal changes, pregnancy care, premature menopause), genetic testing and disease-specific peer support. Women at risk of having unmet needs include those who are younger, with advanced disease, with lymphoedema or a high symptom burden, are unable to work, have mental health issues, have poor social support or live in rural or remote locations. CONCLUSIONS: Understanding the needs of women with gynaecological cancer and their caregivers is essential to improving care and outcomes. Current data are limited thus there is a need for qualitative studies of patient-caregiver dyad and vulnerable subgroups and well-designed quantitative studies of women with each type of gynaecological and their caregivers.


Subject(s)
Caregivers/psychology , Genital Neoplasms, Female/psychology , Social Support , Adult , Female , Humans , Prevalence , Risk Factors
8.
Trials ; 18(1): 470, 2017 Oct 10.
Article in English | MEDLINE | ID: mdl-29017595

ABSTRACT

BACKGROUND: Hypertension is one of the leading causes of morbidity and mortality in Ethiopia. Treatment usually involves lifelong medication use. Enalapril is a common drug for the treatment of hypertension in Ethiopia. However, the drug is expensive and, therefore, there is limited capacity for people to afford the treatment. Locally produced Enalapril is a cost-effective solution to treat the disease. However, as local medicines regulation does not include bioequivalence tests on locally produced drugs, physicians and patients need assurance about the effectiveness and safety of local generics. Evidence on therapeutic equivalence is needed on these untested local drugs. METHODS: This is a hospital-based, randomized, partially blinded, three-cycle crossover trial in single patients, comparing a locally produced version of enalapril with enalapril imported from Europe. Patients involved in this trial are not blinded, as there is no local facility to produce relatively small numbers of placebos or encapsulated drugs. To ensure blinding of study investigators and data analysts, study medications are prepared by an independent pharmacy unit using opaque medication packaging. The importance of maintaining blinding is also part of patient pre-trial education. Each N-of-1 trial will consist of three successive 14-day treatment pairs, each pair comprising 7 days of 5-20 mg local and 7 days of 5-20 mg imported enalapril taken once daily in the morning. The primary outcome will be the average difference in systolic blood pressure as measured by home blood pressure measurements. DISCUSSION: The number of locally produced products, such as enalapril, being approved without proof of bioequivalence is dramatically increasing. By bridging the information gap on bioequivalence, the trial will give rigorous evidence on therapeutic equivalence of locally produced enalapril in the treatment of hypertension. If there is no difference, the hypothesized result, then patients can take the local medicine with confidence. This trial will also will determine whether aggregated N-of-1 studies are feasible to evaluate untested generic drugs in resource-limited countries where bioequivalence testing centers are unavailable. TRIAL REGISTRATION NUMBER: Australian and New Zealand Clinical Trial Registry, ID: ACTRN12616001088437p . Registered on 12 August 2016.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Drug Substitution , Drugs, Generic/therapeutic use , Enalapril/therapeutic use , Hypertension/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Angiotensin-Converting Enzyme Inhibitors/chemistry , Antihypertensive Agents/adverse effects , Antihypertensive Agents/chemistry , Clinical Protocols , Cross-Over Studies , Double-Blind Method , Drug Compounding , Drug Substitution/adverse effects , Drugs, Generic/adverse effects , Drugs, Generic/chemistry , Enalapril/adverse effects , Enalapril/chemistry , Ethiopia , Female , Humans , Hypertension/diagnosis , Hypertension/physiopathology , Male , Middle Aged , Research Design , Therapeutic Equivalency , Time Factors , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...